Newsletter

May 2019 Scorecard

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: May Scorecard Number of Signals 6 Percent Correct – Prev Close to 5-day Peak 83% Avg Increase – Next open to 5-day Peak 7% Other stats: Number of signals over $10/share 3 Number […]

0Comments

La Jolla Pharmaceutical Announces Positive Phase 2 Results of LJPC-401

On June 6, La Jolla Pharmaceutical Company (LJPC) announced positive clinical trial results from its Phase 2 study of LJPC-401. This was a pre-specified interim analysis of its synthetic human hepcidin in patients with hereditary hemochromatosis (HH). Patients experienced statistically significant efficacy levels and tolerated the drug well.   Rocket Tickers detected the news event […]

0Comments

April 2019 Scorecard

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: April Scorecard Number of Signals 4 Percent Correct – Prev Close to 5-day Peak 100% Avg Increase – Next open to 5-day Peak 100% Other stats: Number of signals over $10/share 2 Number […]

0Comments

March 2019 Scorecard

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: January Scorecard Number of Signals 15 Percent Correct – Prev Close to 5-day Peak 100% Avg Increase – Next open to 5-day Peak 10% Other stats: Number of signals over $10/share 8 Number […]

0Comments

Lannett Receives FDA Approval for Aspirin and Extended-Release Dipyridamole Capsules

On March 27, Lannett Company, Inc. (LCI) reported that they have received FDA approval for their Abbreviated New Drug Application (ANDA) for Aspirin and Extended-Release Dipyridamole Capsules, 25mg/200mg. The drug is the therapeutic equivalent to Aggrenox Capsules, 25 mg/200 mg by Boehringer Ingelheim Pharmaceuticals. Total annual sales in the US for Aspirin and Extended-Release Dipyridamole […]

0Comments

February 2019 Scorecard

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: January Scorecard Number of Signals 11 Percent Correct – Prev Close to 5-day Peak 100% Avg Increase – Next open to 5-day Peak 6% Other stats: Number of signals over $10/share 9 Number […]

0Comments

Allakos Reports Positive Phase 1 Clinical Trial Results for AK002

On February 19, Allakos, Inc. (ALLK) announced positive Phase 1 clinical trial results for its drug AK002, which is used to treat eosinophil and mast cell related diseases. The drug is being tested on patients with indolent systemic mastocytosis (ISM), a debilitating disorder caused by the release of inflammatory mediators from mast cells, who had […]

0Comments

January 2019 Scorecard

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: January Scorecard Number of Signals 10 Percent Correct – Prev Close to 5-day Peak 90% Avg Increase – Next open to 5-day Peak 8% Other stats: Number of signals over $10/share 6 Number […]

0Comments

December 2018 Scorecard

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: December Scorecard Number of Signals 12 Percent Correct – Prev Close to 5-day Peak 75% Avg Increase – Next open to 5-day Peak 7% Other stats: Number of signals over $10/share 12 Number […]

0Comments

November 2018 Scorecard

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: November Scorecard Number of Signals 8 Percent Correct – Prev Close to 5-day Peak 88% Avg Increase – Next open to 5-day Peak 8% Other stats: Number of signals over $10/share 5 Number […]

0Comments